Three-year study will test biopsy analysis tool shown in trials to identify men likely to benefit from certain drugsA tool that uses artificial intelligence to help diagnose men with prostate cancer and guide decisions about treatment is to be tested in NHS hospitals, researchers have announced.The £1.9m Vanguard Path study, funded by Prostate Cancer UK and led by researchers at the University of Oxford, is expected to last three years and will test an AI tool called the ArteraAI Prostate Biopsy Assay. In total, biopsies from more than 4,000 men will be used. Continue reading...